Skip to main content
SpringerLink
Log in

Antiemetic Drugs

  • Chapter
  • First Online:
Book cover Prevention of Nausea and Vomiting in Cancer Patients

  • 826 Accesses

Abstract

With modern antiemetics, vomiting can be completely prevented in up to 70–80 % of patients [1–3]. Combination antiemetic regimens have become the standard of care for the control of chemotherapy-induced nausea and vomiting (CINV) [4].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 49.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Hesketh PJ, Grunberg S, Gralla R, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomised, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin. J Clin Oncol. 2003; 21: 4112-4119.

    Google Scholar 

  2. Jordan K, Sippel C, Schmoll HJ. Guidelines for antiemetic treatment of chemotherapy-induced nausea and vomiting: past, present, and future recommendations. Oncologist. 2007;12:1143-1150.

    Google Scholar 

  3. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapyinduced nausea and vomiting. Results from a randomised, double-blind, placebo-controlled trial in Latin America. Cancer. 2003;97:3090-3098.

    Google Scholar 

  4. Hesketh PJ. Chemotherapy-induced nausea and vomiting. N Engl J Med. 2008;358:2482-2494.

    Google Scholar 

  5. Jordan K, Hinke A, Grothey A, Schmoll HJ. Granisetron versus tropisetron for prophylaxis of acute chemotherapy-induced emesis: a pooled analysis. Support Care Cancer. 2005;13:26-31.

    Google Scholar 

  6. Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol. 2007;61:162-175.

    Google Scholar 

  7. Jordan K, Hinke A, Grothey A, et al. A meta-analysis comparing the efficacy of four 5-HT3–receptor antagonists for acute chemotherapy-induced emesis. Support Care Cancer. 2007;15:1023-1033.

    Google Scholar 

  8. Rojas C, Thomas AG, Alt J, et al. Palonosetron triggers 5-HT(3) receptor internalization and causes prolonged inhibition of receptor function. Eur J Pharmacol. 2010; 626:193-199.

    Google Scholar 

  9. Rojas C, Li Y, Zhang J, et al. The antiemetic 5-HT 3 receptor antagonist palonosetron inhibits substance P-mediated responses in vitro and in vivo. J Pharmacol Exp Ther. 2010;335:362-368.

    Google Scholar 

  10. Navari RM. Palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients with cancer. Future Oncol. 2010; 6:1073-1084.

    Google Scholar 

  11. Ruhlmann C, Herrstedt J. Palonosetron hydrochloride for the prevention of chemotherapyinduced nausea and vomiting. Expert Rev Anticancer Ther. 2010;10:137-148.

    Google Scholar 

  12. Kris MG, Hesketh PJ, Somerfield MR, et al. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006;24:2932-2947.

    Google Scholar 

  13. Roila F, Hesketh PJ, Herrstedt J. Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol. 2006;17:20-28.

    Google Scholar 

  14. Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference Ann Oncol. 2010:21(suppl 5):v232-v243.

    Google Scholar 

  15. Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer. 2003;98:2473-2482.

    Google Scholar 

  16. Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapyinduced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomised phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol. 2003;14:1570-1577.

    Google Scholar 

  17. Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a doubleblind, double-dummy, randomised, comparative phase III trial. Lancet Oncol. 2009;10:115-124.

    Google Scholar 

  18. Ettinger DS, Dwight D, MG K, eds. National Comprehensive Cancer Network: Antiemesis, Clinical Practice Guidelines in Oncology. Jenkintown, PA: National Comprehensive Cancer Network; 2005.

    Google Scholar 

  19. Gralla RJ, Osoba D, Kris MG, et al. Recommendations for the use of antiemetics: evidencebased, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol. 1999;17:2971-2994.

    Google Scholar 

  20. Kris MG, Hesketh PJ, Herrstedt J, et al. Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer. 2005;13:85-96.

    Google Scholar 

  21. Goodin S, Cunningham R. 5-HT(3)-receptor antagonists for the treatment of nausea and vomiting: a reappraisal of their side-effect profile. Oncologist. 2002;7:424-436.

    Google Scholar 

  22. Grunberg SM. Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. Ann Oncol. 2007;18:233-240.

    Google Scholar 

  23. Aapro MS, Walko CM. Aprepitant: drug–drug interactions in perspective. Ann Oncol. 2010;21:2316-2323.

    Google Scholar 

  24. Italian Group for Antiemetic Research. Double-blind, dose-finding study of four intravenous doses of dexamethasone in the prevention of cisplatin-induced acute emesis. J Clin Oncol. 1998;16:2937-2942.

    Google Scholar 

  25. Italian Group for Antiemetic Research. Randomised, double-blind, dose-finding study of dexamethasone in preventing acute emesis induced by anthracyclines, carboplatin, or cyclophosphamide. J Clin Oncol. 2004;22:725-729.

    Google Scholar 

  26. Vardy J, Chiew KS, Galica J, et al. Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer. 2006;94:1011-1015.

    Google Scholar 

  27. Aapro M, Fabi A, Nolè F, et al. Double-blind, randomised, controlled study of the efficacy and tolerability of palonosetron plus dexamethasone for 1 day with or without dexamethasone on days 2 and 3 in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Ann Oncol. 2010;21:1083-1088.

    Google Scholar 

  28. Herr I, Ucur E, Herzer K, et al. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas. Cancer Res. 2003;63:3112-3120.

    Google Scholar 

  29. Schmoll HJ, Aapro MS, Poli-Bigelli S, et al. Comparison of an aprepitant regimen with a multipleday ondansetron regimen, both with dexamethasone, for antiemetic efficacy in highdose cisplatin treatment. Ann Oncol. 2006;17:1000-1006.

    Google Scholar 

  30. Rapoport B, Jordan K, Boice J, et al. Aprepitant for the prevention of chemotherapyinduced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomised, double-blind study. Support Care Cancer. 2010;18:423-431.

    Google Scholar 

  31. Warr D, Grunberg, SM, Gralla, RJ, et al. The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer. 2005; 41:1278-1285.

    Google Scholar 

  32. Chawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer. 2003;97:2290-2300.

    Google Scholar 

  33. Grunberg SM, Chua DT, Maru A, et al. and the PN017 study group. Phase III randomized doubleblind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting. J Clin Oncol. 2010;28(suppl):Abstract 9021.

    Google Scholar 

  34. Depre M, Van Hecken A, Oeyen M, et al. Effect of aprepitant on the pharmacokinetics and pharmacodynamics of warfarin. Eur J Clin Pharmacol. 2005;61:341-346.

    Google Scholar 

  35. Shadle CR, Lee Y, Majumdar AK, et al. Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J Clin Pharmacol. 2004;44:215-223.

    Google Scholar 

  36. Dando TM, Perry CM. Aprepitant: a review of its use in the prevention of chemotherapyinduced nausea and vomiting. Drugs. 2004;64:777-794.

    Google Scholar 

  37. Massaro AM, Lenz KL. Aprepitant: a novel antiemetic for chemotherapy-induced nausea and vomiting. Ann Pharmacother. 2005;39:77-85.

    Google Scholar 

  38. McCrea JB, Majumdar AK, Goldberg MR, et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone. Clin Pharmacol Ther. 2003;74:17-24.

    Google Scholar 

  39. Nygren P, Hande K, Petty KJ, et al. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients. Cancer Chemother Pharmacol. 2005;55:609-616.

    Google Scholar 

  40. de Jonge M, Huitema A, Holtkamp M, et al. Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism. Cancer Chemother Pharmacol. 2005;56:370-378.

    Google Scholar 

  41. Lohr L. Chemotherapy-induced nausea and vomiting. Cancer J. 2008;14:85-93.

    Google Scholar 

  42. Kris MG, Gralla RJ, Tyson LB, et al. Controlling delayed vomiting: double-blind, randomised trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin. J Clin Oncol. 1989;7:108-114.

    Google Scholar 

  43. Moreno I, Rosell R, Abad A, et al. Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. Eur J Cancer. 1992;28A:1344-1347.

    Google Scholar 

  44. Italian Group for Antiemetic Research. Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Oncol. 1997;15:124-130.

    Google Scholar 

  45. Navari RM, Einhorn LH, Loehrer PJ Sr, et al. A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. Support Care Cancer. 2007;15:1285-1291.

    Google Scholar 

  46. National Comprehensive Cancer Network. Antiemesis, Clinical Practice Guidelines in Oncology. Fort Washington, PA: National Comprehensive Cancer Network; 2010.

    Google Scholar 

  47. Tramer MR, Carroll D, Campbell FA et al. Cannabinoids for control of chemotherapy-induced nausea and vomiting: a quantitative systematic review. BMJ. 2001;323:16-21.

    Google Scholar 

  48. Radbruch L, Nauck F. Review of cannabinoids in the treatment of nausea and vomiting. Schmerz. 2004;18:306-310.

    Google Scholar 

  49. Kris MG, Gralla RJ, Clark RA, et al. Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomised trial. Cancer. 1987;60:2816-2822.

    Google Scholar 

  50. Sharma SS, Gupta YK. Reversal of cisplatin-induced delay in gastric emptying in rats by ginger (Zingiber officinale). J Ethnopharmacol. 1998 62:49-55.

    Google Scholar 

  51. Dupuis LL, Nathan PC. Options for the prevention and management of acute chemotherapyinduced nausea and vomiting in children. Paediatr Drugs. 2003;5:597-613.

    Google Scholar 

  52. Manusirivithaya S, Sripramote M, Tangjitgamol S, et al. Antiemetic effect of ginger in gynecologic oncology patients receiving cisplatin. Int J Gynecol Cancer. 2004;14:1063-1069.

    Google Scholar 

  53. Ryan JL, Heckler C, Dakhil SR, et al. Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomised, double-blind, placebo-controlled clinical trial of 644 cancer patients. J Clin Oncol. 2009;27(suppl):15 s.

    Google Scholar 

  54. Koretz RL, Rotblatt M. Complementary and alternative medicine in gastroenterology: the good, the bad, and the ugly. Clin Gastroenterol Hepatol. 2004;2:957-967.

    Google Scholar 

  55. Tate S. Peppermint oil: a treatment for postoperative nausea. J Adv Nurs. 1997;26:543-549.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Multidisciplinary Oncology Institute Clinique de Genolier, Genolier, Vaud, Switzerland

    Matti Aapro

  2. Department of Oncology/Haematology, Martin Luther University Hospital Clinic for Internal Medicine, Halle, Germany

    Karin Jordan

  3. Radioonkologie und Nuklearmedizin, Vivantes Klinikum Neukölln Klinik für Strahlentherapie, Berlin, Germany

    Petra Feye

Authors
  1. Matti Aapro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karin Jordan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Petra Feye
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Petra Feye .

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Healthcare

About this chapter

Cite this chapter

Aapro, M., Jordan, K., Feye, P. (2013). Antiemetic Drugs. In: Prevention of Nausea and Vomiting in Cancer Patients. Springer Healthcare, Tarporley. https://doi.org/10.1007/978-1-907673-58-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-907673-58-0_5

  • Published:

  • Publisher Name: Springer Healthcare, Tarporley

  • Print ISBN: 978-1-908517-87-6

  • Online ISBN: 978-1-907673-58-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation